浸润性肾脏肿物的完整谱系:临床特征与预后意义
回顾性分析2008—2017年280例影像学识别为浸润性肾脏肿物的患者,其中265例确诊为浸润性肾脏肿物。中位年龄65岁、肿瘤大小6.9 cm,85%为R.E.N.A.L.评分10—12分;68%有症状,66%为局部晚期(cT3—T4),68%有播散性疾病和/或淋巴结肿大(>2 cm)。58%死亡,52%为癌症相关死亡,中位5个月。
要点
- 浸润性肾脏肿物多为有症状、低分化、高致死性恶性肿瘤。
- 肾细胞癌94例(35%),其中49例为高侵袭性组织学;高级别尿路上皮癌70例(26%)。
- 仅31%接受肾脏手术,27%接受全身化疗,22%接受靶向治疗。
核心结论
- 本系列涵盖浸润性肾脏肿物的完整谱系,证实其以有症状、低分化、高致死性恶性肿瘤为主。
- 研究强调在评估肾脏肿物时识别浸润性特征这一简单影像学诊断具有压倒性重要性。
研究设计与样本
- 回顾性分析2008—2017年连续280例影像学识别为具有浸润性特征的肾脏肿物患者。
- 浸润性肾脏肿物定义为肿瘤与肾实质界面不清且在一个或多个明确区域呈不规则形状(非椭圆形)。
- 最终265例确诊为浸润性肾脏肿物并评估临床特征与结局。
主要发现
- 中位年龄65岁,中位肿瘤大小6.9 cm,225例(85%)R.E.N.A.L.评分为10—12分。
- 181例(68%)有症状就诊,176例(66%)为局部晚期癌症(cT3—T4),181例(68%)有播散性疾病和/或淋巴结肿大(>2 cm)。
- 103例接受肾脏肿物活检,97例(94%)诊断明确。
- 82例(31%)接受肾脏手术,其中3例(1.1%)为肾部分切除术;72例(27%)接受全身化疗,59例(22%)接受靶向治疗。
- 最终诊断:肾细胞癌94例(35%),包括49例高侵袭性组织学(肉瘤样/横纹肌样/集合管/髓样/未分类);高级别尿路上皮癌70例(26%);淋巴瘤26例(10%);转移性癌25例(9%)。
临床怎么用
- 临床和影像学表现可提示病因并指导评估,但对明确诊断无特异性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the full spectrum of patients presenting with radiologically-identified infiltrative renal masses (IRMs), including those managed surgically or otherwise, with focus on clinical presentation/prognosis. METHODS: All 280 patients presenting with radiologically-identified renal mass with infiltrative features (2008-2017) were retrospectively reviewed. Poorly-defined interface between tumor and parenchyma and irregular shape (nonelliptical) in one or more distinct/unequivocal areas were required for classification as IRM. IRM was confirmed in 265 and clinical characteristics and outcomes were assessed. RESULTS: Median age/tumor size were 65-years/6.9 cm, respectively, and 225 patients (85%) were R.E.N.A.L. = 10-12. Overall, 181 patients (68%) presented symptomatically, locally-advanced cancer (cT3-T4) was observed in 176 (66%) and disseminated disease and/or lymphadenopathy (>2 cm) in 181(68%). Clinical/radiographic findings were suggestive of etiology and could direct evaluation, but were nonspecific for definitive diagnosis. Renal-mass biopsy was performed in 103 patients and diagnostic in 97 (94%). Renal surgery was only performed in 82 patients (31%) and partial nephrectomy in 3 (1.1%). Overall, 72 patients (27%) received systemic chemotherapy and 59 (22%) targeted therapy. Final-diagnosis was renal cell carcinoma in 94 patients (35%), including 49 with highly-aggressive histology (sarcomatoid/rhabdoid/collecting-duct/medullary/unclassified). High-grade urothelial-carcinoma was found in 70 (26%), and lymphoma/metastatic cancer in 26 (10%)/25 (9%), respectively. Overall, 153 patients (58%) died; 138 (52%) cancer-related at median of 5 months. The majority of patients with renal cell carcinoma, urothelial-carcinoma, and renal metastasis died, almost exclusively cancer-related, at medians of 8, 3, and 2 months, respectively. CONCLUSION: Our series includes the full spectrum of IRMs and confirms predominance of symptomatic, poorly-differentiated, highly-lethal malignancies. Our study highlights the overriding importance of identifying infiltrative features, a simple radiologic diagnosis, during assessment of renal masses.
引用
- Wang Y, Tanaka H, Ye Y, et al. The Complete Spectrum of Infiltrative Renal Masses: Clinical Characteristics and Prognostic Implications. Urology. 2019. PMID: 31075276. doi:10.1016/j.urology.2019.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。